These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33334939)

  • 1. The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial.
    Jenkins CR; Wen FQ; Martin A; Barnes PJ; Celli B; Zhong NS; Zheng JP; Scaria A; Di Tanna GL; Bradbury T; Berend N;
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial.
    Bradbury T; Di Tanna GL; Scaria A; Martin A; Wen FQ; Zhong NS; Zheng JP; Barnes PJ; Celli B; Berend N; Jenkins CR;
    Int J Chron Obstruct Pulmon Dis; 2022; 17():273-282. PubMed ID: 35153479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
    Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Trials; 2015 Jun; 16():267. PubMed ID: 26058585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B; Markham A
    Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
    Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
    Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
    Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
    Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.